ITU512 / Novartis - LARVOL DELTA

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease (clinicaltrials.gov) - P1/2 | N=161 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2029 ➔ Dec 2029 | Trial primary completion date: Nov 2027 ➔ Jul 2028

Trial completion date • Trial primary completion date • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease (clinicaltrials.gov) - P1/2 | N=161 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease (clinicaltrials.gov) - P1/2 | N=138 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P1/2 trial • Genetic Disorders • Hematological Disorders • Sickle Cell Disease